Semarion is a University of Cambridge spin-out from the Cavendish Laboratory developing next-generation tools to accelerate cell-based drug discovery. Its proprietary SemaCyte® platform turns adherent cells into barcoded, assay-ready, automation-friendly reagents, enabling researchers to multiplex cell models, increase throughput, and generate richer datasets using existing tools and workflows. Semarion is combining materials engineering, microfabrication, and cell biology to remove bottlenecks in adherent cell assays and unlock 10x gains in data generation.